Abstract:Background & aims: The effectiveness of immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) is limited by treatment resistance. However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in resistance to anti-PD-1 therapy in HCC. Methods: Gene expression in HCC specimens from 10 patients receiving anti-PD-1 therapy was identified by RNA-sequencing. A total of 404 HCC samples from tissue microarrays were analyzed by immunohistochemistry. Transgenic mice (Alb-Cre/Trp53fl/fl) received hydrodynamic tail vein injections of a CRKL-overexpressing vector. Mass cytometry by time of flight was used to profile the proportion and status of different immune cell lineages in the mouse tumor tissues. Results: CRKL was identified as a candidate anti-PD-1-resistance gene using a pooled genetic screen. CRKL overexpression nullifies anti-PD-1 treatment efficacy by mobilizing tumor-associated neutrophils (TANs), which block the infiltration and function of CD8+ T cells. PD-L1+ TANs were found to be an essential subset of TANs that were regulated by CRKL expression and display an immunosuppressive phenotype. Mechanistically, CRKL inhibits APC (adenomatous polyposis coli)-mediated proteasomal degradation of β-catenin by competitively decreasing Axin1 binding, and thus promotes VEGFα and CXCL1 expression. Using human HCC samples, we verified the positive correlations of CRKL/β-catenin/VEGFα and CXCL1. Targeting CRKL using CRISPR-Cas9 gene editing (CRKL knockout) or its downstream regulators effectively restored the efficacy of anti-PD-1 therapy in an orthotopic mouse model and a patient-derived organotypic tumor spheroid model. Conclusions: Activation of the CRKL/β-catenin/VEGFα and CXCL1 axis is a critical obstacle to successful anti-PD-1 therapy. Therefore, CRKL inhibitors combined with anti-PD-1 could be useful for the treatment of HCC. Impact and implications: Here, we found that CRKL was overexpressed in anti-PD-1-resistant hepatocellular carcinoma (HCC) and that CRKL upregulation promotes anti-PD-1 resistance in HCC. We identified that upregulation of the CRKL/β-catenin/VEGFα and CXCL1 axis contributes to anti-PD-1 tolerance by promoting infiltration of tumor-associated neutrophils. These findings support the strategy of bevacizumab-based immune checkpoint inhibitor combination therapy, and CRKL inhibitors combined with anti-PD-1 therapy may be developed for the treatment of HCC.

CRKL is a Critical Target of Hh-GLI2 Pathway in Lung Adenocarcinoma.

The Novel KLF4/PLAC8 Signaling Pathway Regulates Lung Cancer Growth.

CRL2KLHDC3 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression

Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy

Akt kinase LANCL2 functions as a key driver in EGFR -mutant lung adenocarcinoma tumorigenesis

CRKL Knockdown Promotes in Vitro Proliferation, Migration and Invasion, in Vivo Tumor Malignancy and Lymph Node Metastasis of Murine Hepatocarcinoma Hca-P Cells

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma

Downregulation of CRKL Expression Can Inhibit Tumorigenesis in Colon Cancer.

CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer

CRISPLD1 Promotes Gastric Cancer Progression by Regulating the Ca2+/PI3K-AKT Signaling Pathway

Non-canonical GLI1/2 Activation by PI3K/AKT Signaling in Renal Cell Carcinoma: A Novel Potential Therapeutic Target.

Identification of CRKL as an oncogenic biomarker for prognosis and immunotherapy in melanoma, and its potential molecular mechanism

KLRB1 expression is associated with lung adenocarcinoma prognosis and immune infiltration and regulates lung adenocarcinoma cell proliferation and metastasis through the MAPK/ERK pathway

Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness

Knockdown of CRAD suppresses the growth and promotes the apoptosis of human lung cancer cells via Claudin 4

Inhibition of CK2α Down-Regulates Hedgehog/Gli Signaling Leading to a Reduction of a Stem-Like Side Population in Human Lung Cancer Cells

CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma

KRAS/PI3K Axis Driven GTF3C6 Expression and Promotes LUAD Via FAK Pathway

Identification ofLBX2as a novel causal gene of lung adenocarcinoma

HOXC11 Drives Lung Adenocarcinoma Progression Through Transcriptional Regulation of SPHK1.

Suppression of Tumorigenesis in LUAD by LRP1B Through Regulation of the IL-6-JAK-STAT3 Pathway.